Citigroup Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target decreased by stock analysts at Citigroup from $16.50 to $13.25 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “sell” rating on the stock. Citigroup’s price target points to a potential downside of 14.59% from the company’s previous close.

Several other equities analysts have also commented on HIMS. Morgan Stanley set a $21.00 price target on shares of Hims & Hers Health in a research report on Tuesday. Bank of America decreased their target price on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, February 9th. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $33.91.

Hims & Hers Health Price Performance

Shares of HIMS traded up $0.00 on Tuesday, reaching $15.51. The stock had a trading volume of 41,878,764 shares, compared to its average volume of 27,557,242. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $3.53 billion, a PE ratio of 28.76, a PEG ratio of 2.92 and a beta of 2.43. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The firm has a 50-day moving average of $28.21 and a 200 day moving average of $40.02.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period in the previous year, the firm posted $0.11 EPS. Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has initiated a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,090 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the transaction, the chief financial officer directly owned 94,333 shares of the company’s stock, valued at approximately $3,369,574.76. This trade represents a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider directly owned 2,126 shares of the company’s stock, valued at $78,045.46. This represents a 79.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 82,963 shares of company stock valued at $2,944,621 in the last three months. 17.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter valued at $26,000. Quent Capital LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Finally, Quaker Wealth Management LLC bought a new stake in Hims & Hers Health during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q4 beat on profitability and continuing subscriber/revenue growth — Hims & Hers topped EPS expectations and reported ~28% YoY revenue growth, showing improving unit economics that support longer‑term profitability. Read More.
• Positive Sentiment: Full‑year 2026 revenue framework aims at growth and international expansion — management guided 2026 revenue to $2.7B–$2.9B and is accelerating global expansion (including the announced Eucalyptus acquisition) to broaden its addressable market. Those initiatives could support revenue upside if execution stays on track. Read More. Read More.
• Neutral Sentiment: Earnings call highlighted strategy and investments — management emphasized record growth, tech investments and specialty launches while discussing regulatory scrutiny; the long‑term strategy remains intact but near‑term execution risk is higher. Read More.
• Negative Sentiment: Soft Q1 2026 sales guidance missed Street expectations — the company guided Q1 revenue to $600M–$625M versus a consensus near ~$650M, which undercut near‑term growth visibility and is a primary reason shares moved lower. Read More.
• Negative Sentiment: SEC investigation disclosed related to copycat/compounded GLP‑1 products — new regulatory/legal scrutiny raises potential compliance costs, product restrictions or liability, increasing execution risk for HIMS’s high‑growth weight‑loss business. Read More.
• Negative Sentiment: Analyst sentiment turned more cautious — BTIG downgraded HIMS from Buy to Neutral after the report, amplifying downside pressure as institutional flows respond to weaker guidance and regulatory headlines. Read More.
• Negative Sentiment: Market commentary frames the move as regulatory‑led outlook damage — several outlets interpret the combination of softer guidance and regulatory risk as the main driver of the selloff. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.